On The Pen Live Eps 67: Survodutide Trial Participant Tells All!

Send us a text In this week’s episode of On The Pen Live, guest Scott Liberto of PlanetScott.com joins to discuss his experience in the Survodutide clinical trial. Survodutide is an investigational dual agonist targeting both the glucagon and GLP-1 receptors, developed by Boehringer Ingelheim in collaboration with Zealand Pharma. This novel drug is designed to treat obesity and metabolic dysfunction-associated steatohepatitis (MASH). ro.co/OTP Support the show Our Book Has Been Released! Decoding GLP-1: A Guide for Friends and Family of Those On The Pen Buy Here: https://amzn.to/3Dc66d4 DNF10 Peptide Supplement I Use: https://integrativepeptides.com/AFFILITATES/OTP USE CODE "OTP10" to save 10%. A small commission is paid back to support On The Pen! MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT: Venmo: OnThePen Ca$h App: ManOnMounjaro BECOME A MEMBER: https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join 👉 My Amazon Affiliate Store: https://www.amazon.com/shop/manonthemounjaroonthepen MORE COMMUNITY! 📺 Watch Our Weekly Live Show: onthepen.tv 🆕 Discord: https://discord.gg/u4Ea8qqP 🤝 Visit Our Sponsor! GLP-1 Ro Body Plan: https://www.ro.co/otp Report The Shortage: https://www.ro.co/supply-tracker Does your insurance cover GLPs? https://www.ro.com/checker 📲 Contact Me: dave@onthepen.com Thank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and... Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.